In the final segment of this series, Drs. Morris, Garmezy, and Chen discuss the use of novel radiopharmaceuticals. In the fourth part of this series, the panelists discuss barriers to the use of radium-223 and other radioligands. In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy. In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC. In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible. In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials. In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments. The challenges of patient management and access to care are explored in the sixth part of our RLT roundtable discussion. The fifth segment of the RLT roundtable explores recent clinical trials, including the VISION study. The fourth part of this roundtable delves into the VISION and PSMAfore studies and their implications. The third part of this roundtable explores imaging interpretation and toxicity management. An expert panel discusses the evolving landscape of radioligand therapy for prostate cancer. The panel discusses the role of PSMA imaging in prostate cancer, theranostics, and radioligand therapy. In part 3 of this series, the panelists review the latest game-changing studies in prostate cancer and CRPC from ESMO 2024. In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed. In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC. In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC. In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed. In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC. In part 3 of this roundtable, the NIAGARA trial is discussed, along with cisplatin regimens and the potential of durvalumab.